Moreover, several pharmacological protocols using medications such as HMG-CoA-reductase inhibitors or commonly referred to as statins, AT2R antagonists, and Ca2+-channel blockers increase the expression/activity of eNOS, that in turn, can benefit CVD via attenuating endothelial dysfunction and promoting global and regional blood flow [216]. This evidence concerns the gene NOS3 and endothelial dysfunction.